Forskning ved Københavns Universitet - Københavns Universitet

Forside

MYCN amplification drives an aggressive form of spinal ependymoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

MYCN amplification drives an aggressive form of spinal ependymoma. / Ghasemi, David R; Sill, Martin; Okonechnikov, Konstantin; Korshunov, Andrey; Yip, Stephen; Schutz, Peter W; Scheie, David; Kruse, Anders; Harter, Patrick N; Kastelan, Marina; Wagner, Marlies; Hartmann, Christian; Benzel, Julia; Maass, Kendra K; Khasraw, Mustafa; Sträter, Ronald; Thomas, Christian; Paulus, Werner; Kratz, Christian P; Witt, Hendrik; Kawauchi, Daisuke; Herold-Mende, Christel; Sahm, Felix; Brandner, Sebastian; Kool, Marcel; Jones, David T W; von Deimling, Andreas; Pfister, Stefan M; Reuss, David E; Pajtler, Kristian W.

I: Acta Neuropathologica, Bind 138, Nr. 6, 2019, s. 1075-1089.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Ghasemi, DR, Sill, M, Okonechnikov, K, Korshunov, A, Yip, S, Schutz, PW, Scheie, D, Kruse, A, Harter, PN, Kastelan, M, Wagner, M, Hartmann, C, Benzel, J, Maass, KK, Khasraw, M, Sträter, R, Thomas, C, Paulus, W, Kratz, CP, Witt, H, Kawauchi, D, Herold-Mende, C, Sahm, F, Brandner, S, Kool, M, Jones, DTW, von Deimling, A, Pfister, SM, Reuss, DE & Pajtler, KW 2019, 'MYCN amplification drives an aggressive form of spinal ependymoma', Acta Neuropathologica, bind 138, nr. 6, s. 1075-1089. https://doi.org/10.1007/s00401-019-02056-2

APA

Ghasemi, D. R., Sill, M., Okonechnikov, K., Korshunov, A., Yip, S., Schutz, P. W., ... Pajtler, K. W. (2019). MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 138(6), 1075-1089. https://doi.org/10.1007/s00401-019-02056-2

Vancouver

Ghasemi DR, Sill M, Okonechnikov K, Korshunov A, Yip S, Schutz PW o.a. MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica. 2019;138(6):1075-1089. https://doi.org/10.1007/s00401-019-02056-2

Author

Ghasemi, David R ; Sill, Martin ; Okonechnikov, Konstantin ; Korshunov, Andrey ; Yip, Stephen ; Schutz, Peter W ; Scheie, David ; Kruse, Anders ; Harter, Patrick N ; Kastelan, Marina ; Wagner, Marlies ; Hartmann, Christian ; Benzel, Julia ; Maass, Kendra K ; Khasraw, Mustafa ; Sträter, Ronald ; Thomas, Christian ; Paulus, Werner ; Kratz, Christian P ; Witt, Hendrik ; Kawauchi, Daisuke ; Herold-Mende, Christel ; Sahm, Felix ; Brandner, Sebastian ; Kool, Marcel ; Jones, David T W ; von Deimling, Andreas ; Pfister, Stefan M ; Reuss, David E ; Pajtler, Kristian W. / MYCN amplification drives an aggressive form of spinal ependymoma. I: Acta Neuropathologica. 2019 ; Bind 138, Nr. 6. s. 1075-1089.

Bibtex

@article{65100cdfbc8b46fb9005ba7482785f56,
title = "MYCN amplification drives an aggressive form of spinal ependymoma",
abstract = "Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous system (CNS) occurs and, in these cases, clinical outcome remains poor. Here, we describe a new and relatively rare subgroup of spinal ependymal tumors identified using DNA methylation profiling that is distinct from other molecular subgroups of ependymoma. Copy number variation plots derived from DNA methylation arrays showed MYCN amplification as a characteristic genetic alteration in all cases of our cohort (n = 13), which was subsequently validated using fluorescence in situ hybridization. The histological diagnosis was anaplastic ependymoma (WHO Grade III) in ten cases and classic ependymoma (WHO Grade II) in three cases. Histological re-evaluation in five primary tumors and seven relapses showed characteristic histological features of ependymoma, namely pseudorosettes, GFAP- and EMA positivity. Electron microscopy revealed cilia, complex intercellular junctions and intermediate filaments in a representative sample. Taking these findings into account, we suggest to designate this molecular subgroup spinal ependymoma with MYCN amplification, SP-EPN-MYCN. SP-EPN-MYCN tumors showed distinct growth patterns with intradural, extramedullary localization mostly within the thoracic and cervical spine, diffuse leptomeningeal spread throughout the whole CNS and infiltrative invasion of the spinal cord. Dissemination was observed in 100{\%} of cases. Despite high-intensity treatment, SP-EPN-MYCN showed significantly worse median progression free survival (PFS) (17 months) and median overall survival (OS) (87 months) than all other previously described molecular spinal ependymoma subgroups. OS and PFS were similar to supratentorial ependymoma with RELA-fusion (ST-EPN-RELA) and posterior fossa ependymoma A (PF-EPN-A), further highlighting the aggressiveness of this distinct new subgroup. We, therefore, propose to establish SP-EPN-MYCN as a new molecular subgroup in ependymoma and advocate for testing newly diagnosed spinal ependymal tumors for MYCN amplification.",
author = "Ghasemi, {David R} and Martin Sill and Konstantin Okonechnikov and Andrey Korshunov and Stephen Yip and Schutz, {Peter W} and David Scheie and Anders Kruse and Harter, {Patrick N} and Marina Kastelan and Marlies Wagner and Christian Hartmann and Julia Benzel and Maass, {Kendra K} and Mustafa Khasraw and Ronald Str{\"a}ter and Christian Thomas and Werner Paulus and Kratz, {Christian P} and Hendrik Witt and Daisuke Kawauchi and Christel Herold-Mende and Felix Sahm and Sebastian Brandner and Marcel Kool and Jones, {David T W} and {von Deimling}, Andreas and Pfister, {Stefan M} and Reuss, {David E} and Pajtler, {Kristian W}",
year = "2019",
doi = "10.1007/s00401-019-02056-2",
language = "English",
volume = "138",
pages = "1075--1089",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer",
number = "6",

}

RIS

TY - JOUR

T1 - MYCN amplification drives an aggressive form of spinal ependymoma

AU - Ghasemi, David R

AU - Sill, Martin

AU - Okonechnikov, Konstantin

AU - Korshunov, Andrey

AU - Yip, Stephen

AU - Schutz, Peter W

AU - Scheie, David

AU - Kruse, Anders

AU - Harter, Patrick N

AU - Kastelan, Marina

AU - Wagner, Marlies

AU - Hartmann, Christian

AU - Benzel, Julia

AU - Maass, Kendra K

AU - Khasraw, Mustafa

AU - Sträter, Ronald

AU - Thomas, Christian

AU - Paulus, Werner

AU - Kratz, Christian P

AU - Witt, Hendrik

AU - Kawauchi, Daisuke

AU - Herold-Mende, Christel

AU - Sahm, Felix

AU - Brandner, Sebastian

AU - Kool, Marcel

AU - Jones, David T W

AU - von Deimling, Andreas

AU - Pfister, Stefan M

AU - Reuss, David E

AU - Pajtler, Kristian W

PY - 2019

Y1 - 2019

N2 - Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous system (CNS) occurs and, in these cases, clinical outcome remains poor. Here, we describe a new and relatively rare subgroup of spinal ependymal tumors identified using DNA methylation profiling that is distinct from other molecular subgroups of ependymoma. Copy number variation plots derived from DNA methylation arrays showed MYCN amplification as a characteristic genetic alteration in all cases of our cohort (n = 13), which was subsequently validated using fluorescence in situ hybridization. The histological diagnosis was anaplastic ependymoma (WHO Grade III) in ten cases and classic ependymoma (WHO Grade II) in three cases. Histological re-evaluation in five primary tumors and seven relapses showed characteristic histological features of ependymoma, namely pseudorosettes, GFAP- and EMA positivity. Electron microscopy revealed cilia, complex intercellular junctions and intermediate filaments in a representative sample. Taking these findings into account, we suggest to designate this molecular subgroup spinal ependymoma with MYCN amplification, SP-EPN-MYCN. SP-EPN-MYCN tumors showed distinct growth patterns with intradural, extramedullary localization mostly within the thoracic and cervical spine, diffuse leptomeningeal spread throughout the whole CNS and infiltrative invasion of the spinal cord. Dissemination was observed in 100% of cases. Despite high-intensity treatment, SP-EPN-MYCN showed significantly worse median progression free survival (PFS) (17 months) and median overall survival (OS) (87 months) than all other previously described molecular spinal ependymoma subgroups. OS and PFS were similar to supratentorial ependymoma with RELA-fusion (ST-EPN-RELA) and posterior fossa ependymoma A (PF-EPN-A), further highlighting the aggressiveness of this distinct new subgroup. We, therefore, propose to establish SP-EPN-MYCN as a new molecular subgroup in ependymoma and advocate for testing newly diagnosed spinal ependymal tumors for MYCN amplification.

AB - Spinal ependymal tumors form a histologically and molecularly heterogeneous group of tumors with generally good prognosis. However, their treatment can be challenging if infiltration of the spinal cord or dissemination throughout the central nervous system (CNS) occurs and, in these cases, clinical outcome remains poor. Here, we describe a new and relatively rare subgroup of spinal ependymal tumors identified using DNA methylation profiling that is distinct from other molecular subgroups of ependymoma. Copy number variation plots derived from DNA methylation arrays showed MYCN amplification as a characteristic genetic alteration in all cases of our cohort (n = 13), which was subsequently validated using fluorescence in situ hybridization. The histological diagnosis was anaplastic ependymoma (WHO Grade III) in ten cases and classic ependymoma (WHO Grade II) in three cases. Histological re-evaluation in five primary tumors and seven relapses showed characteristic histological features of ependymoma, namely pseudorosettes, GFAP- and EMA positivity. Electron microscopy revealed cilia, complex intercellular junctions and intermediate filaments in a representative sample. Taking these findings into account, we suggest to designate this molecular subgroup spinal ependymoma with MYCN amplification, SP-EPN-MYCN. SP-EPN-MYCN tumors showed distinct growth patterns with intradural, extramedullary localization mostly within the thoracic and cervical spine, diffuse leptomeningeal spread throughout the whole CNS and infiltrative invasion of the spinal cord. Dissemination was observed in 100% of cases. Despite high-intensity treatment, SP-EPN-MYCN showed significantly worse median progression free survival (PFS) (17 months) and median overall survival (OS) (87 months) than all other previously described molecular spinal ependymoma subgroups. OS and PFS were similar to supratentorial ependymoma with RELA-fusion (ST-EPN-RELA) and posterior fossa ependymoma A (PF-EPN-A), further highlighting the aggressiveness of this distinct new subgroup. We, therefore, propose to establish SP-EPN-MYCN as a new molecular subgroup in ependymoma and advocate for testing newly diagnosed spinal ependymal tumors for MYCN amplification.

U2 - 10.1007/s00401-019-02056-2

DO - 10.1007/s00401-019-02056-2

M3 - Journal article

C2 - 31414211

VL - 138

SP - 1075

EP - 1089

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 6

ER -

ID: 241645246